Compounders Research Compare

BriaCell Therapeutics Corp.(BCTX)

Biotechnology · West Vancouver, BC

$4.20+0.02 (+0.48%)

Delayed quote: Oct 6, 2026, 9:30 AM EDT

About BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company primarily focused on developing innovative immunotherapies to combat cancer. The firm's leading experimental drug, Bria-IMT, is currently undergoing Phase I/IIa clinical investigation. This crucial study evaluates its effectiveness when utilized in conjunction with immune checkpoint inhibitors for treating breast cancer. Beyond its flagship program, BriaCell has forged a collaborative research and development partnership with the National Cancer Institute (NCI). This alliance is dedicated to progressing Bria-OTS, a personalized immunotherapy designed for advanced breast cancer patients, and BriaDx, a proprietary diagnostic assay. The company's main offices are situated in West Vancouver, Canada.

West Vancouver, BC

16 employees

www.briacell.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: William V. Williams

View full financials

BriaCell Therapeutics (BCTX) EV/EBITDA: History & Chart | TGMCharts

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T13:30:42.742Z.

Stored calculation inputs

Calculation as of: 2026-10-06T13:30:42.742Z.

Quote observation: 2026-10-06T13:30:00.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 36,539,118
Total debt · period ending 2026-04-30: 0
Cash · period ending 2026-04-30: 6,880,221
TTM operating EBITDA · period ending 2026-04-30: -38,509,715

FMP input reference: 8e18e4937bb179ad65bb801f5f057f36d78bd2e4af2c39ec5cecdad017acf428

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

BCTX EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

BCTX Competitors' EV/EBITDA Ratio

BriaCell Therapeutics Corp.

Current

Market Cap

$36.54M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Elutia Inc

Market Cap

$35.68M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HeartBeam, Inc.

Market Cap

$34.65M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Elicio Therapeutics, Inc.

Market Cap

$36.23M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DocGo Inc.

Market Cap

$36.79M

EV/EBITDA Ratio

N/A

TTM Avg

6.76x

3Y Avg

19.14x

5Y Avg

45.56x

Accuray Incorporated

Market Cap

$36.26M

EV/EBITDA Ratio

N/A

TTM Avg

25.79x

3Y Avg

51.85x

5Y Avg

38.84x

Edesa Biotech, Inc.

Market Cap

$37.67M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Harvard Bioscience, Inc.

Market Cap

$38.38M

EV/EBITDA Ratio

10.51x

TTM Avg

9.64x

3Y Avg

45.33x

5Y Avg

52.62x

Incannex Healthcare Limited

Market Cap

$38.29M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Grace Therapeutics, Inc.

Market Cap

$33.85M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
BriaCell Therapeutics Corp. (BCTX)	$36.54M	N/A	N/A	N/A	N/A
Elutia Inc (ELUT)vs ›	$35.68M	N/A	N/A	N/A	N/A
HeartBeam, Inc. (BEAT)vs ›	$34.65M	N/A	N/A	N/A	N/A
Elicio Therapeutics, Inc. (ELTX)vs ›	$36.23M	N/A	N/A	N/A	N/A
DocGo Inc. (DCGO)vs ›	$36.79M	N/A	6.76x	19.14x	45.56x
Accuray Incorporated (ARAY)vs ›	$36.26M	N/A	25.79x	51.85x	38.84x
Edesa Biotech, Inc. (EDSA)vs ›	$37.67M	N/A	N/A	N/A	N/A
Harvard Bioscience, Inc. (HBIO)vs ›	$38.38M	10.51x	9.64x	45.33x	52.62x
Incannex Healthcare Limited (IXHL)vs ›	$38.29M	N/A	N/A	N/A	N/A
Grace Therapeutics, Inc. (GRCE)vs ›	$33.85M	N/A	N/A	N/A	N/A

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics